Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 1996;93:400-402

This Article
Right arrow Full Text
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Williams, D. O.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Williams, D. O.

(Circulation. 1996;93:400-402.)
© 1996 American Heart Association, Inc.


Articles

Dressing Up the Palmaz-Schatz Stent

David O. Williams, MD

From the Division of Cardiology, Department of Medicine, Rhode Island Hospital, Brown University, Providence, RI.

Correspondence to David O. Williams, MD, Division of Cardiology, Rhode Island Hospital, Providence, RI 02903.


Key Words: Editorials • angioplasty • stents • heparin • coronary disease


*    Introduction
 
We are approaching the 20th anniversary of the first use of coronary balloon angioplasty in humans. This nonsurgical treatment of obstructive coronary atherosclerosis has proved effective in relieving subjective and objective manifestations of myocardial ischemia, with recent clinical trials demonstrating comparability with coronary artery bypass surgery in selected patients with advanced multivessel disease (References 1 through 5 and personal observations). Despite impressive technical refinements of equipment and technique, balloon angioplasty continues to be plagued by three major limitations: (1) inability to treat certain types of coronary lesions, particularly those presenting as chronic total occlusion; (2) the potential of acutely aggravating coronary obstruction by means of coronary dissection, spasm, or thrombosis necessitating emergency coronary bypass surgery or causing myocardial infarction; and (3) recurrence of coronary narrowing 3 to 6 months after initial treatment.

New devices have been developed in response to these shortcomings. Directional atherectomy can remove a component of the obstructive atherosclerotic plaque, but clinical superiority over conventional balloon angioplasty has been questioned.6 7 8 High-speed rotational atherectomy drills plaque and allows treatment of certain coronary narrowings that cannot be treated with a balloon catheter and appears to enhance the effectiveness and safety of conventional angioplasty for patients with complex lesions.9 10 11 Efforts are ongoing to determine whether debulking lesions alone or in conjunction with balloon angioplasty will reduce the chance of lesion recurrence.12 Devices such as direct laser angioplasty, laser-heated balloon angioplasty, and extraction atherectomy have been shown to be feasible techniques, but their marginal utility has been null or minimal.

Coronary . . . [Full Text of this Article]




This article has been cited by other articles:


Home page
Cardiovasc ResHome page
D. Brieger and E. Topol
Local drug delivery systems and prevention of restenosis
Cardiovasc Res, September 1, 1997; 35(3): 405 - 413.
[Full Text] [PDF]